Known targets — ChEMBL curated mechanism
ADRA2AADRA2BADRA2CADRB2AGTR1AVPR1AAVPR1BAVPR2BDKRB2CALCRCHRNA3CHRNB4ESR1ESR2GHSRGNRHRGSC1HSPA8MALT1MC1RMC4RNOS1NOS2NOS3OPRK1OXTRRAMP1RAMP2RAMP3SCN5ASSTR1SSTR2SSTR3SSTR4SSTR5dacAdacBdacCfolPftsImrcAmrcBmrdArplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Acetic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR3 | O14843 | 3/20 | 0.58 |
| ▸ | LCK | P06239 | 1/20 | 0.58 |
| ▸ | FYN | P06241 | 1/20 | 0.58 |
| ▸ | LMNA | P02545 | 4/20 | 0.50 |
| ▸ | TSHR | P16473 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.38 |
| ▸ | CA4 | P22748 | 2/20 | 0.38 |
| ▸ | SLC15A2 | Q16348 | 1/20 | 0.37 |
| ▸ | THPO | P40225 | 1/20 | 0.36 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | CA1 | P00915 | 2/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
| ▸ | BLM | P54132 | 1/20 | 0.33 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.33 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.32 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.32 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.32 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Acetic Acid SCHEMBL28661347 | 0.96 | FFAR3 (0.54) | FFAR3LCKFYNLMNATSHR | |
| Acetic Acid SCHEMBL8785366 | 0.96 | FFAR3 (0.64) | FFAR3LCKFYNLMNATSHR | |
| Acetic Acid SCHEMBL28343178 | 0.96 | FFAR3 (0.64) | FFAR3LCKFYNLMNATSHR | |
| Acetic Acid SCHEMBL282406 | 0.96 | — | — | |
| Acetic Acid SCHEMBL2706810 | 0.96 | FFAR3 (0.64) | FFAR3LCKFYNLMNATSHR | |
| Acetic Acid SCHEMBL5035361 | 0.96 | — | — | |
| Acetic Acid SCHEMBL7309563 | 0.92 | — | — | |
| Acetic Acid SCHEMBL17479019 | 0.92 | — | — | |
| Acetic Acid SCHEMBL10743699 | 0.92 | FFAR3 (0.58) | FFAR3LCKFYNLMNATSHR | |
| Acetic Acid SCHEMBL59820 | 0.92 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 60 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2016054568-A1 | SELECTIVE 3-O-ALKYLATION OF METHYL ALPHA-L-RHAMNOPYRANOSIDE | DOW AGROSCIENCES LLC (US) | 2016-04-07 | — | — | WO | disclosed |
| WO-2016054505-A1 | PROCESS FOR THE PREPARATION OF PURE METHYL 3-O-(ALKYL OR ALKENYL)- ALPHA-L-RHAMNOPYRANOSIDE AND 3-O-(ALKYL OR ALKENYL)-2,4-DI-O-ALKYL ALPHA-L-RHAMNOPYRANOSIDE | DOW AGROSCIENCES LLC (US) | 2016-04-07 | — | — | WO | disclosed |
| WO-2016054564-A1 | SELECTIVE 3-O-ALKYLATION OF METHYL ALPHA-L-RHAMNOPYRANOSIDE | DOW AGROSCIENCES LLC (US) | 2016-04-07 | — | — | WO | disclosed |
| WO-2016054539-A1 | SELECTIVE 3-O-ALKYLATION OF METHYL ALPHA-L-RHAMNOPYRANOSIDE | DOW AGROSCIENCES LLC (US) | 2016-04-07 | — | — | WO | disclosed |
| WO-2016054573-A1 | SELECTIVE 3-O-ALKYLATION OF METHYL ALPHA-L-RHAMNOPYRANOSIDE | DOW AGROSCIENCES LLC (US) | 2016-04-07 | — | — | WO | disclosed |
| US-20140147887-A1 | NOVEL 12 ALPHA-HYDROXYSTEROID DEHYDROGENASES, PRODUCTION AND USE THEREOF | PHARMAZELL GMBH (DE) | 2014-05-29 | — | — | US | disclosed |
| US-20130079289-A1 | Pharmaceutical Compositions | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-03-28 | — | — | US | disclosed |
| US-20120083441-A1 | Pharmaceutical Compositions | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-04-05 | — | — | US | disclosed |
| US-20110091921-A1 | NOVEL 12 ALPHA-HYDROXYSTEROID DEHYDROGENASES, PRODUCTION AND USE THEREOF | PHARMAZELL GMBH (DE) | 2011-04-21 | — | — | US | disclosed |
| US-20100267744-A1 | Pharmaceutical Compositions | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-10-21 | — | — | US | disclosed |
| US-4927963-A | Novel processes for the synthesis of certain bicyclo(4.2.0)octane derivatives with valuable therapeutic properties | SYNTEX (U.S.A.) INC. (US) | 1990-05-22 | — | — | US | disclosed |
| EP-0291234-A2 | Peptidic human leukocyte elastase (HLE) inhibitors | ZENECA INC. (US) | 1988-11-17 | — | — | EP | disclosed |
| US-4431591-A | 24-Nor-1,4-choladiene-3,22-dione | KNIGHT JOHN C | 1984-02-14 | — | — | US | disclosed |
| US-4429041-A | Process of producing 9-hydroxy-3-oxo-4,17(20)-pregnadiene-20-carboxylic acid | THE UPJOHN COMPANY (US) | 1984-01-31 | — | — | US | disclosed |
| US-4425429-A | Composition of matter and process | THE UPJOHN COMPANY (US) | 1984-01-10 | — | — | US | disclosed |
| US-4423146-A | Composition of matter and process | THE UPJOHN COMPANY (US) | 1983-12-27 | — | — | US | disclosed |
| US-4405525-A | Composition of matter and process | THE UPJOHN COMPANY (US) | 1983-09-20 | — | — | US | disclosed |
| US-4112087-A | Cephalosporin type antibacterials having a substituted propenyl group in the 3-position | SYNTEX (U.S.A.) INC. (US) | 1978-09-05 | — | — | US | disclosed |
| US-3995056-A | Butyric acid derivatives for treating pain and inflammation | ROUSSEL-UCLAF (FR) | 1976-11-30 | — | — | US | disclosed |
| US-3931302-A | ANTIINFLAMMATORY, ANALGESIC | ROUSSEL-UCLAF (FR) | 1976-01-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110091921-A1 | NOVEL 12 ALPHA-HYDROXYSTEROID DEHYDROGENASES, PRODUCTION AND USE THEREOF | CYP46A1, HSD11B1, DHCR7 | FFAR3 1492/4885LCK 4389/4885FYN 3820/4885 |
| US-20100267744-A1 | Pharmaceutical Compositions | LPXN, VCL, VNN1 | FFAR3 2270/4885LCK 3838/4885FYN 3227/4885 |
| US-20120083441-A1 | Pharmaceutical Compositions | LPXN, VCL, VNN1 | FFAR3 2270/4885LCK 3838/4885FYN 3227/4885 |
| US-20130079289-A1 | Pharmaceutical Compositions | LPXN, VCL, VNN1 | FFAR3 2270/4885LCK 3839/4885FYN 3227/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.